Invalidity dossier
US 12030959
Added 5/26/2026, 6:00:54 PM
⚖️ Active PTAB challenge: 1 pending proceeding against this patent
1 active — Inter Partes Review, Post-Grant Review, or Covered Business Method proceedings at the USPTO Patent Trial and Appeal Board.
Got a demand letter citing US 12030959?
Paste the full letter into the analyzer. We extract every asserted patent (this one and any others), characterize the asserter, flag validity vulnerabilities, and draft a sample response letter your attorney can adapt.
Generic sample response letter (PDF)
Generates a draft reply letter to a generic infringement claim citing this patent, using the analysis below. For a response tailored to a specific letter you received, use the demand letter analyzer instead. Sample only — not legal advice. Do not send without review by a licensed patent attorney.
Watchlist
Get alerted when this patent moves.
Email-only, free, anonymous. We'll notify you when US 12030959 gets a new lawsuit, a new PTAB proceeding, or a new dossier section. One-click unsubscribe from any alert.
Active provider: Google · gemini-2.5-flash
Patent summary
Title, assignee, inventors, filing/issue dates, abstract, and a plain-language overview of the claims.
Here is a concise summary of US patent 12030959:
- Title: Anti-IgE antibody therapy for multiple food allergies
- Assignee(s): Novartis AG and Genentech Inc. The original assignee was Genentech Inc.
- Inventors: Ryan Patrick Owen, Ahmar Iqbal, Robert A. Wood
- Filing Date: October 12, 2023
- Issue Date: July 9, 2024
- Abstract: The patent describes methods and kits for treating or preventing allergic reactions to food allergens in human subjects with one or more food allergies. Specifically, it provides prophylactic therapies involving the administration of an anti-IgE antibody, such as omalizumab, at a specific dose and frequency, to individuals allergic to one or more food allergens.
Independent Claims Overview:
The provided patent text does not contain a "Claims" section, therefore, a plain-language overview of each independent claim cannot be provided.
USPTO Database Search:
A search for US Patent 12030959B1 indicates that the patent is "Active" as of the publication date. Further detailed post-grant events (e.g., reexaminations, specific assignments beyond what's listed, or maintenance fee status) were not explicitly found through the conducted search snippets, beyond the general legal status provided by Google Patents. The USPTO provides a Patent Public Search tool for such detailed inquiries.
CAFC 2026 Dockets Search:
A review of the U.S. Court of Appeals for the Federal Circuit (CAFC) 2026 dockets did not reveal any cases specifically mentioning patent number 12030959. This suggests that, as of April 26, 2026, there are no active appeals related to this patent in the publicly available 2026 dockets.
Generated 5/26/2026, 6:01:34 PM